Medical abortion. Medical abortion
Conditions
Interventions
Intervention 1: Intervention group 1: Vaginal misoprostol, produced by Pfizer Company, 600 µg every 4 hours for 5 days in women with the gestational age of 13 weeks or less and 200 µg every 4 hours f
Treatment - Drugs
Intervention group 1: Vaginal misoprostol, produced by Pfizer Company, 600 µg every 4 hours for 5 days in women with the gestational age of 13 weeks or less and 200 µg every 4 hours for 5 days in wom
Intervention group 2: Oral letrozole, produced by Iran Hormon Company, 10 mg daily and vaginal misoprostol, produced by Pfizer Company, 600 µg every 4 hours for 5 days for women in the gestational age
Intervention group 3: vaginal laminaria, produced by Cytotec Company, 5mm for 6 hours and vaginal misoprostol, produced by Pfizer Company, 600 µg every 4 hours for 5 days for women in the gestational
Sponsors
Vice chancellor for research, Ardabil University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria: Under 20 weeks pregnancy and fetal death. Exclusion criteria: Cesarean section history; adrenal diseases; asthma; history of thromboembolism
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fetus abortion. Timepoint: Eight hours after the intervention, and every twenty-four hours up to three days if the abortion doesn't occur. Method of measurement: Transvaginal Ultrasonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: Every four hours until abortion occurs and at the time that abortion occurs. Method of measurement: Visual analog scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mahsa Valaee
Ardabil University of Medical Sciences
Outcome results
None listed